276 related articles for article (PubMed ID: 28642233)
1. Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
Borroni E; Bohrmann B; Grueninger F; Prinssen E; Nave S; Loetscher H; Chinta SJ; Rajagopalan S; Rane A; Siddiqui A; Ellenbroek B; Messer J; Pähler A; Andersen JK; Wyler R; Cesura AM
J Pharmacol Exp Ther; 2017 Sep; 362(3):413-423. PubMed ID: 28642233
[TBL] [Abstract][Full Text] [Related]
2. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
Sturm S; Forsberg A; Nave S; Stenkrona P; Seneca N; Varrone A; Comley RA; Fazio P; Jamois C; Nakao R; Ejduk Z; Al-Tawil N; Akenine U; Halldin C; Andreasen N; Ricci B
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):382-391. PubMed ID: 27633250
[TBL] [Abstract][Full Text] [Related]
3. Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD).
Nave S; Doody RS; Boada M; Grimmer T; Savola JM; Delmar P; Pauly-Evers M; Nikolcheva T; Czech C; Borroni E; Ricci B; Dukart J; Mannino M; Carey T; Moran E; Gilaberte I; Muelhardt NM; Gerlach I; Santarelli L; Ostrowitzki S; Fontoura P
J Alzheimers Dis; 2017; 58(4):1217-1228. PubMed ID: 28550255
[TBL] [Abstract][Full Text] [Related]
4. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
5. Role of Monoamine Oxidase Activity in Alzheimer's Disease: An Insight into the Therapeutic Potential of Inhibitors.
Behl T; Kaur D; Sehgal A; Singh S; Sharma N; Zengin G; Andronie-Cioara FL; Toma MM; Bungau S; Bumbu AG
Molecules; 2021 Jun; 26(12):. PubMed ID: 34207264
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
Manzoor S; Hoda N
Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
[TBL] [Abstract][Full Text] [Related]
7. TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease.
Weinstock M; Bejar C; Wang RH; Poltyrev T; Gross A; Finberg JP; Youdim MB
J Neural Transm Suppl; 2000; (60):157-69. PubMed ID: 11205137
[TBL] [Abstract][Full Text] [Related]
8. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
Gulyás B; Pavlova E; Kása P; Gulya K; Bakota L; Várszegi S; Keller E; Horváth MC; Nag S; Hermecz I; Magyar K; Halldin C
Neurochem Int; 2011 Jan; 58(1):60-8. PubMed ID: 21075154
[TBL] [Abstract][Full Text] [Related]
9. Newly developed reversible MAO-B inhibitor circumvents the shortcomings of irreversible inhibitors in Alzheimer's disease.
Park JH; Ju YH; Choi JW; Song HJ; Jang BK; Woo J; Chun H; Kim HJ; Shin SJ; Yarishkin O; Jo S; Park M; Yeon SK; Kim S; Kim J; Nam MH; Londhe AM; Kim J; Cho SJ; Cho S; Lee C; Hwang SY; Kim SW; Oh SJ; Cho J; Pae AN; Lee CJ; Park KD
Sci Adv; 2019 Mar; 5(3):eaav0316. PubMed ID: 30906861
[TBL] [Abstract][Full Text] [Related]
10. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease.
Thomas T
Neurobiol Aging; 2000; 21(2):343-8. PubMed ID: 10867219
[TBL] [Abstract][Full Text] [Related]
11. MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway.
Coatrieux C; Sanson M; Negre-Salvayre A; Parini A; Hannun Y; Itohara S; Salvayre R; Auge N
Free Radic Biol Med; 2007 Jul; 43(1):80-9. PubMed ID: 17561096
[TBL] [Abstract][Full Text] [Related]
12. Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels.
Schedin-Weiss S; Inoue M; Hromadkova L; Teranishi Y; Yamamoto NG; Wiehager B; Bogdanovic N; Winblad B; Sandebring-Matton A; Frykman S; Tjernberg LO
Alzheimers Res Ther; 2017 Aug; 9(1):57. PubMed ID: 28764767
[TBL] [Abstract][Full Text] [Related]
13. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
14. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
Naoi M; Riederer P; Maruyama W
J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation.
Youdim MB; Weinstock M
Neurotoxicology; 2004 Jan; 25(1-2):243-50. PubMed ID: 14697899
[TBL] [Abstract][Full Text] [Related]
16. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
Guay DR
Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
[TBL] [Abstract][Full Text] [Related]
17. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
18. Characterization of monoamine oxidase-B (MAO-B) as a biomarker of reactive astrogliosis in Alzheimer's disease and related dementias.
Jaisa-Aad M; Muñoz-Castro C; Healey MA; Hyman BT; Serrano-Pozo A
Acta Neuropathol; 2024 Apr; 147(1):66. PubMed ID: 38568475
[TBL] [Abstract][Full Text] [Related]
19. Effect of MAO-B inhibition against ischemia-induced oxidative stress in the rat brain. Comparison with a rational antioxidant.
Seif-El-Nasr M; Atia AS; Abdelsalam RM
Arzneimittelforschung; 2008; 58(4):160-7. PubMed ID: 18540477
[TBL] [Abstract][Full Text] [Related]
20. Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review).
Cai Z
Mol Med Rep; 2014 May; 9(5):1533-41. PubMed ID: 24626484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
